Lifecore Biomedical, Inc.
NASDAQ:LFCRDrug Manufacturers - Specialty & Generic
+$0.02 today
- Market cap
- $242.60M
- Beta
- 1.07
- P/E (TTM)
- -6.1
- EPS (TTM)
- -$0.91
Volume 0.15M
Average 0.29M
LFCR Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Lifecore Biomedical, Inc.NASDAQ: LFCR
Net Income · Q3 FY2026 · quarter ended Mar 2026
Net income of -$14.98M in Q3 FY2026
Q3 FY2026 net income was -$14.98M. Trailing-twelve-month net income was -$34.09M. Over 3 fiscal years it compounded at -30.8% a year.
Context
- Net income amounted to 30.0% of revenue in FY2025, up 20.7 pp from a year earlier.
- Net income increased in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 1 analysts of -$16.71M (-56.8%) for the fiscal year ending May 2026, a step up from the -422.3% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$14.98M+88.0% QoQ
- Last fiscal yearMay 2025
- -$38.72M-422.3% YoY
- LTMMar 2026
- -$34.09M— YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | — | — |
| 1 year | -422.3% | -56.8% | +365.5 pp |
| 3-year CAGR | -30.8% | -4.0% | +26.8 pp |
| 5-year CAGR | -10.2% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (38.72M) USD
- Year-over-year change
- -422.3%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-05-25 | (38.72M) | -422.3% |
| FY2024 | 2024-05-26 | 12.01M | +112.1% |
| FY2023 | 2023-05-28 | (99.56M) | +14.7% |
| FY2022 | 2022-05-29 | (116.72M) | -261.4% |
| FY2021 | 2021-05-31 | (32.29M) | — |
Net Income vs competitors
How LFCR compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Net income amounts to 25.2% of revenue for LFCR, versus a peer median of 90.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$286.21M CAD | -52.6% | -50.8% | 91.6% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $89.93M USD | +26.6% | +26.6% | 871.8% |
| FY2025 | A$61.43M AUD | +43.8% | +24.0% | 1218.0% | |
| LTM Mar 2026 | CA$58.58M CAD | -507.7% | -39.5% | 18.8% | |
| LTM Mar 2026 | $52.66M USD | +2.2% | +8.8% | 89.1% | |
| LTM Mar 2026 | $51.99M USD | +12.6% | +8.9% | — | |
| LTM Mar 2026 | €45.62M EUR | +51.2% | -14.2% | 339.4% | |
| LTM Mar 2026 | $37.25M USD | -24.6% | -23.6% | 46.8% | |
| LTM Mar 2026 | $34.09M USD | — | -30.8% | 25.2% | |
| LTM Mar 2026 | $17.17M USD | -26.3% | -28.6% | 41.1% | |
| Peer median (excluding LFCR) | — | +2.2% | -14.2% | 90.4% | |
Competitors are the stored peer set for LFCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 May 2021 | FY2022 May 2022 | FY2023 May 2023 | FY2024 May 2024 | FY2025 May 2025 |
|---|---|---|---|---|---|
| Net Income | (32.29M) | (116.72M) | (99.56M) | 12.01M | (38.72M) |
| Depreciation & Amortization | 19.87M | 18.06M | 13.18M | 7.95M | 8.03M |
| Deferred Income Tax | (7.87M) | (6.83M) | 357K | 163K | 0 |
| Stock-Based Compensation | 3.36M | 2.61M | 3.61M | 6.2M | 10.16M |
| Change in Working Capital | 9.76M | (3.1M) | 19.79M | (3.7M) | (4.7M) |
| Accounts Receivables | 5.78M | (6.14M) | 10.82M | (2.39M) | (2.26M) |
| Inventory | (2.82M) | (2.18M) | (14.81M) | 862K | 7.69M |
| Accounts Payables | (5.98M) | 9.34M | 16.04M | (6.68M) | (1.67M) |
| Other Working Capital | 12.79M | (4.13M) | 7.74M | 4.51M | (8.45M) |
| Other Non-Cash Items | 23.65M | 83.38M | 45.19M | (22.38M) | 25.02M |
| Operating Cash Flow | 16.47M | (22.59M) | (17.44M) | 257K | (206K) |
| Capital Expenditures | (25.22M) | (29.94M) | (21.48M) | (18.4M) | (13.42M) |
| Acquisitions (Net) | 0 | 73.5M | 16.67M | 0 | 7M |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 45.1M | 0 | 0 | 0 |
| Other Investing Activities | 12.91M | (8.7M) | 0 | 0 | 0 |
| Investing Cash Flow | (12.31M) | 79.96M | (4.81M) | (18.4M) | (6.42M) |
| Debt Repayment | 7.47M | (55.41M) | 3.12M | 2.17M | (18.56M) |
| Common Stock Issued | 0 | 0 | 4.82M | 0 | 23.85M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (10.89M) | (1.61M) | (6.32M) | 5.34M | 1.13M |
| Financing Cash Flow | (3.42M) | (57.02M) | 39.7M | 7.51M | 6.42M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 742K | 348K | 17.45M | (10.63M) | (197K) |
| Free Cash Flow | (8.75M) | (52.53M) | (38.92M) | (18.14M) | (13.62M) |
Lifecore Biomedical, Inc.
NASDAQ:LFCR
Intrinsic Alpha fair value
Locked
Current Price
$6.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.